Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma

Background: Although TP53 co-mutation with KRAS/ATM/EGFR/STK11 have been proved to have predictive value for response to immune checkpoint inhibitors (ICIs), not all TP53 mutations are equal in this context. As the main part of TP53 mutant types, Missense and Nonsense alternations in TP53 as indepen...

Full description

Bibliographic Details
Main Authors: Hao Sun, Si-Yang Liu, Jia-Ying Zhou, Jin-Tian Xu, Huang-Kai Zhang, Hong-Hong Yan, Jiao-Jiao Huan, Ping-Ping Dai, Chong-Rui Xu, Jian Su, Yan-Fang Guan, Xin Yi, Rong-Shan Yu, Wen-Zhao Zhong, Yi-Long Wu
Format: Article
Language:English
Published: Elsevier 2020-10-01
Series:EBioMedicine
Subjects:
TP53
Lung adenocarcinoma
Immunotherapy
Subtypes
Online Access:http://www.sciencedirect.com/science/article/pii/S2352396420303662

Internet

http://www.sciencedirect.com/science/article/pii/S2352396420303662

Similar Items